Dr. Axe Wire · Breaking · health
FDA Adds Vision-Loss Warning to Ozempic, Zepbound and All GLP-1 Drugs
Ozempic, Wegovy, Zepbound and Mounjaro will carry a new label warning about a rare eye condition linked to irreversible vision loss.

CBS News reported on November 9, 2026, that the FDA will add a warning about a rare eye condition called non-arteritic anterior ischemic optic neuropathy, or NAION, to the labels of every GLP-1 drug.
The FDA said Monday it will add the NAION warning to every GLP-1 drug, a class of a dozen injectable and pill-based medicines that includes Ozempic, Wegovy, Zepbound and Mounjaro. Across more than 125 clinical trials, the agency counted about 6 NAION cases per 100,000 people on a GLP-1 for a year or longer, compared with fewer than 4 per 100,000 among those on placebo or other glucose-lowering medications. The FDA also found NAION cases in its reporting system for drug side effects. Symptoms include blurred vision, blind spots and distorted colors, and the FDA says anyone noticing these should contact a healthcare professional right away.
Novo Nordisk, which makes Ozempic and Wegovy, said it doesn't think the data show its drugs cause NAION, and that it stands by the benefit-risk balance of its GLP-1 medicines. Eli Lilly, which makes Zepbound and Mounjaro, said it is evaluating the update.
NAION happens when blood flow to the optic nerve drops, damaging the fibers that carry visual signals to the brain; the FDA said why GLP-1 drugs might raise this risk isn't understood. NAION also strikes people who never take these drugs, roughly 2 to 10 per 100,000 adults past age 50. Dr. Joseph Rizzo, a neuro-ophthalmologist who co-authored the 2024 paper that first flagged the link, told CBS News the evidence shows GLP-1 use raises NAION risk, but he still does not discourage patients from taking these drugs given their broader benefits.
NAION Cases per 100,000 Patients Over One Year
The FDA has not found a way to predict who is affected or to reduce the risk. Rizzo said vision loss tends to be permanent and can worsen even after stopping the drug, and damage in one eye doesn't predict how severe damage in the second eye might be.
Dr. Axe’s Take
This warning is worth taking seriously, even though the absolute risk is still small, a few extra cases per 100,000 people a year. I pair GLP-1 medicines with a whole-food diet, high protein, fiber-rich vegetables and regular resistance training, because the drug alone doesn't rebuild the muscle and metabolic health people need long term. Many people also do well on a much lower dose, often 10 to 20% of the labeled dose, worked out with the prescribing doctor rather than adjusted on your own. If you notice sudden vision changes, blurred spots or distorted colors, contact your doctor right away, and don't stop or change your dose on your own.
— Dr. AxeTake the Metabolic Health Quiz →
Story summary
- Who
- Adults on GLP-1 drugs across more than 125 clinical trials; general NAION background rate 2 to 10 per 100,000 adults over 50 (American Academy of Ophthalmology)
- Design
- FDA safety review of pooled clinical trial data plus adverse-event reports
- Primary result
- NAION occurred in about 6 per 100,000 patients on a GLP-1 for at least one year, versus fewer than 4 per 100,000 on placebo or other glucose-lowering drugs
- Secondary
- Vision loss often irreversible; symptoms include blurred vision, blind spots, distorted colors; second-eye severity not predicted by first-eye severity
- Date
- Nov 9, 2026



